pacv investor relations as of feb. 2022 is mz group telephone number on bottom page.

https://pacvgroup.com/pacific-ventures-group-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-communication-program/

10,470,916 million total volume today t trade 4.49 million

10,470,916 million total volume today t trade 4.49 million

iam not convinced of dilution here at pacv since the dollar volume of daly trades hardly amounts to much money generated- would scarcely make a dent in paying
pacv bills.

according to pinksheets.com no change in pacv o/s since last week.to 10/31/22

Outstanding Shares
340,951,025
10/24/2022

Outstanding Shares
340,951,025
10/31/2022

nice bid !

no change this past week unrestricted shares at
95,555,170
10/31/2022

Unrestricted
95,555,170
10/24/2022

looks like another t trade for pacv 2,672,783 at .0042? hope some good news arrives soon.

looks like another t trade for pacv 2,672,783 at .0042.? hope some good news arrives soon.

exciting times ahead for pacv when the new online website for seaportsteak is launched .

will be interesting to see how long pacv will take to pivot to their next phase-
{ houston and online sales.}

hoping pacv closes on the midwest [texas]$40 million meat processing cos . will our selling price soar past .25 then?

appreciate it docj and i added a few at .0036 today also.hope they run pacv soon !

pacv share update 10/10/2022 Outstanding Shares no change unrestricted shares no change.
330,951,025
10/10/2022
Restricted
245,395,855
10/10/2022
Unrestricted
85,555,170
10/10/2022

based off of this proactive video seaport meats should be going online shortly? definitely will increase revenue.

i just picked up a few PACV to start the day.

great article on gourmet ranch opening a very large meat processing facility in n.w, houston.imo pacv is going in the right direction.
https://www.bizjournals.com/houston/news/2022/05/27/gourmet-ranch-new-meat-processing-plant.html

"The company said the meat-processing plant will allow for growth in production and new hires to meet the growing demand for meat products and online consumer buying."

i picked up more .004s earlier because i feel this agressive management will close on the houston meat facility doing $40 million revs for their next online delivery to homes venture.

glad i picked up some shares will see what cos brings

dont blame you an r/s is a stock killer a matter of trust issue.right now unrestricted share count pretty low at 85,555,170.

just curious hd2001 whether pacv has anything working at this time? i see last year march there was a LOI to purchase a midwest meat and beverage cos.

was not too pleased about the extra 350 million shares being added to the a/s so was going to vote my shares no, but i feel
that dr jay laz and his nih old ties helped procure the recent grants like what dr jonah sachi will use leronlimab in his new hiv study. so was looking for an excuse to vote yes and the nih
grants moved the needle for me to vote yes.and that grant money seems to be the only positive of this year for cydy still awaiting king cyrus to make his grand appearance hopefully in a big way.

seeking alpha-CytoDyn: It Only Takes One Hit

https://seekingalpha.com/article/4536813-cytodyn-it-only-takes-one-hit?mailingid=28836316&messageid=2800&serial=28836316.477&source=email_2800&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=28836316.477

https://stockoftheweek.net/stock-report/?symbol=cydy&gclid=EAIaIQobChMIxpaZz6G4-AIV_HZvBB0bHwJrEAMYASAAEgLyFPD_BwE

insider financial- cydy one of four otc stocks to watch

https://insiderfinancial.com/4-otc-stocks-to-watch-cbdd-cybl-cydy-sfor/183287/

i believe he/she cpmes on board,if true, right before nash event?

according to ymb poster pitt28 cytodyn has found a new ceo and feels the new partnership may have picked him/her?

per new 8k out:

(b) On May 17, 2022, Jordan G. Naydenov provided written notice to the Company’s Corporate Secretary of his resignation as a Board member of the Company as of May 17, 2022. He did not give a reason for his resignation.

https://www.otcmarkets.com/filing/html?id=15839654&guid=xXawknO0tQmBh3h

interesting times ! seems maybe someone from the 13d group is writing the new cydy press releases lets hope the new team can close a deal or two besides bad mouthing nader ?

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company.
Under the terms of the agreement, the parties will release each other of all claims, and the Company will release to Dr. Pestell 8.3 million shares of the Company’s common stock held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell.
Antonio Migliarese, Chief Financial Officer and interim President, stated, “We are pleased to resolve this matter as part of our comprehensive efforts to restore credibility with the medical and scientific communities. We look forward to the opportunity to utilize Dr. Pestell’s expertise to further the development of leronlimab.”
Dr. Pestell has published more than 600 works, is the most frequently cited scientist in the field of cell-cycle control and was appointed an Officer of the Order of Australia in the 2019 Queen’s Birthday Honours for distinguished service to medicine and medical education. He has served on editorial boards of six journals, was the Director of two NCI-designated Cancer Centers and has founded several biotechnology companies. He serves as an advisor and reviewer for a number of domestic and international research centers, including NCI cancer centers.

i dont know scott kelly seemed pleased with their mTNBC trial results

https://www.globenewswire.com/news-release/2021/08/25/2286285/19782/en/CytoDyn-s-Final-mTNBC-Report-Indicates-as-Much-as-980-Increase-in-12-Month-Overall-Survival-and-Up-to-660-in-12-Month-Modified-Progression-Free-Survival.html

iam watching the video right now off your quest feed thnx.

"The Court concluded that the Company was likely to succeed on its claims that Amarex breached the various agreements with CytoDyn,and therefore entered an injunction requiring Amarex to provide CytoDyn access to databases of its clinical trial data that Amarex has been wrongfully withholding."

https://www.businesswire.com/news/home/20211222005314/en/CytoDyn-Announces-Favorable-Ruling-Granting-Injunction-Against-Former-CRO

bottom line the fda did a horrible job protecting the public with our covid situation.they pushed leronlimab and other little mab treatments to the back of the bus while rolling out the red carpet for remdesivir and the vaccines. with over a million covid deaths even bill gates weighs in essentially saying keep taking your booster shots if you are over 50 years old until we get even better vaccines.

https://twitter.com/backtolife_2022/status/1525787634714525697?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1525787634714525697%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2022%2F05%2Fbill-gates-says-adults-50-will-probably-get-covid-boosters-every-6-months-get-better-vaccines-video%2F

been hoping for a little update from the brazil covid trials [if still ongoing?] to validate
the effectiveness of leronlimab for four doses for 4 weeks.

"cd-12 was the trial where only 2 doses of leronlimab were administered over the 28 day trial period .there is a table below that shows leronlimab in the critically ill even with the 2 doses bettering placebo by 31%. had leronlimab been given on the 3rd and 4th weeks the trial results would have had been far more improved."

https://www.globenewswire.com/news-release/2021/05/18/2231343/19782/en/CytoDyn-to-Submit-Newly-Completed-Topline-Report-of-CD12-Trial-Results-to-Regulatory-Agencies-in-Multiple-Countries-including-India-and-Philippines.html

appears these inquires to cydy are a year old at least so i doubt much will come of it. not an issue either that leronlimab is a solid treatment for covid plenty of data available to that end.tnbc wow nader mil doing well from circa 2019 LL treatment and beats pretty much all treatments by many months. soon we will learn about our 700 mg as a superior treatment for nash.we already know about LL for hiv. iam looking forward to the months ahead with all the great news cydy will be giving.

The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities

here is the whole paragraph from last years 10q but there is an earlier filing that fierce biotech aug 03 last year did an article on and referred to a sec filing of the matter july 30,2021.

"The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security."

from the 10q last year regarding subpoenas to cydy for the quarterly period ended August 31, 2021 page 24 :

"The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security."

8-k out

https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-22-148819/d650707d8k.htm